LCTX logo

Lineage Cell Therapeutics (LCTX) Shareholders Equity

Annual Shareholders Equity

$63.42 M
-$9.92 M-13.53%

31 December 2023

LCTX Shareholders Equity Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Shareholders Equity

$66.19 M
-$2.11 M-3.10%

30 September 2024

LCTX Quarterly Shareholders Equity Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

LCTX Shareholders Equity Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-13.5%-2.8%
3 y3 years-34.1%-45.2%
5 y5 years-32.4%-43.5%

LCTX Shareholders Equity High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3 years-34.1%at low-45.2%+4.4%
5 y5 years-43.9%at low-46.9%+4.4%
alltimeall time-61.0%+1559.0%-66.6%+1439.9%

Lineage Cell Therapeutics Shareholders Equity History

DateAnnualQuarterly
Sept 2024
-
$66.19 M(-3.1%)
June 2024
-
$68.30 M(-5.7%)
Mar 2024
-
$72.40 M(+14.2%)
Dec 2023
$63.42 M(-13.5%)
$63.42 M(-6.9%)
Sept 2023
-
$68.12 M(-6.3%)
June 2023
-
$72.67 M(+3.1%)
Mar 2023
-
$70.45 M(-3.9%)
Dec 2022
$73.34 M(-20.5%)
$73.34 M(-7.1%)
Sept 2022
-
$78.95 M(-4.7%)
June 2022
-
$82.85 M(-4.3%)
Mar 2022
-
$86.55 M(-6.2%)
Dec 2021
$92.22 M(-4.1%)
$92.22 M(-23.6%)
Sept 2021
-
$120.71 M(-3.2%)
June 2021
-
$124.71 M(+6.0%)
Mar 2021
-
$117.67 M(+22.3%)
Dec 2020
$96.20 M(-14.8%)
$96.20 M(+5.4%)
Sept 2020
-
$91.27 M(-8.2%)
June 2020
-
$99.44 M(-6.6%)
Mar 2020
-
$106.50 M(-5.7%)
Dec 2019
$112.96 M(+20.4%)
$112.96 M(-3.6%)
Sept 2019
-
$117.16 M(-12.2%)
June 2019
-
$133.39 M(-18.1%)
Mar 2019
-
$162.84 M(+73.5%)
Dec 2018
$93.84 M(-42.3%)
$93.84 M(-45.2%)
Sept 2018
-
$171.13 M(+69.5%)
June 2018
-
$100.98 M(+1.0%)
Mar 2018
-
$99.97 M(-38.5%)
Dec 2017
$162.64 M(+37.9%)
$162.64 M(-18.0%)
Sept 2017
-
$198.29 M(+12.6%)
June 2017
-
$176.13 M(-6.0%)
Mar 2017
-
$187.37 M(+58.9%)
Dec 2016
$117.93 M(+356.8%)
$117.93 M(-1.2%)
Sept 2016
-
$119.39 M(+39.2%)
June 2016
-
$85.74 M(+690.1%)
Mar 2016
-
$10.85 M(-58.0%)
Dec 2015
$25.82 M(-29.2%)
$25.82 M(+97.9%)
Sept 2015
-
$13.04 M(-23.2%)
June 2015
-
$16.98 M(-35.3%)
Mar 2015
-
$26.25 M(-28.0%)
Dec 2014
$36.46 M(+146.3%)
$36.46 M(+232.0%)
Sept 2014
-
$10.98 M(-38.7%)
June 2014
-
$17.91 M(-6.9%)
Mar 2014
-
$19.24 M(+30.0%)
Dec 2013
$14.80 M(+54.4%)
$14.80 M(+14.4%)
Sept 2013
-
$12.94 M(-38.1%)
June 2013
-
$20.92 M(+32.0%)
Mar 2013
-
$15.84 M(+65.3%)
Dec 2012
$9.58 M(-66.5%)
$9.58 M(-43.4%)
Sept 2012
-
$16.94 M(-26.9%)
June 2012
-
$23.18 M(-4.2%)
Mar 2012
-
$24.20 M(-15.5%)
Dec 2011
$28.65 M(-25.0%)
$28.65 M(-14.8%)
Sept 2011
-
$33.63 M(-7.0%)
June 2011
-
$36.14 M(-11.5%)
Mar 2011
-
$40.86 M(+7.0%)
Dec 2010
$38.17 M(+441.7%)
$38.17 M(+8.6%)
Sept 2010
-
$35.16 M(+26.6%)
June 2010
-
$27.76 M(+331.0%)
Mar 2010
-
$6.44 M(-8.6%)
Dec 2009
$7.05 M(-262.1%)
$7.05 M(+69.9%)
Sept 2009
-
$4.15 M(-600.9%)
June 2009
-
-$827.80 K(-83.2%)
Mar 2009
-
-$4.94 M(+13.6%)
Dec 2008
-$4.35 M
-$4.35 M(-9.8%)
Sept 2008
-
-$4.82 M(+22.9%)
DateAnnualQuarterly
June 2008
-
-$3.92 M(+17.1%)
Mar 2008
-
-$3.35 M(+10.0%)
Dec 2007
-$3.05 M(+63.3%)
-$3.05 M(+7.1%)
Sept 2007
-
-$2.84 M(+7.9%)
June 2007
-
-$2.64 M(+11.1%)
Mar 2007
-
-$2.37 M(+27.2%)
Dec 2006
-$1.87 M(+848.7%)
-$1.87 M(+19.8%)
Sept 2006
-
-$1.56 M(+27.1%)
June 2006
-
-$1.22 M(+96.2%)
Mar 2006
-
-$624.40 K(+217.6%)
Dec 2005
-$196.60 K(-157.0%)
-$196.60 K(-82.4%)
Sept 2005
-
-$1.11 M(+50.4%)
June 2005
-
-$740.40 K(+130.4%)
Mar 2005
-
-$321.40 K(-193.2%)
Dec 2004
$344.80 K(-114.2%)
$344.80 K(-60.8%)
Sept 2004
-
$880.10 K(-34.0%)
June 2004
-
$1.33 M(-21.7%)
Mar 2004
-
$1.70 M(-170.0%)
Dec 2003
-$2.43 M(+107.5%)
-$2.43 M(+33.1%)
Sept 2003
-
-$1.83 M(-16.9%)
June 2003
-
-$2.20 M(+24.3%)
Mar 2003
-
-$1.77 M(+50.9%)
Dec 2002
-$1.17 M(+1081.7%)
-$1.17 M(+227.8%)
Sept 2002
-
-$357.30 K(-77.0%)
June 2002
-
-$1.55 M(+108.0%)
Mar 2002
-
-$746.80 K(+653.6%)
Dec 2001
-$99.10 K(-107.5%)
-$99.10 K(-90.7%)
Sept 2001
-
-$1.07 M(+528.2%)
June 2001
-
-$170.10 K(-122.6%)
Mar 2001
-
$754.00 K(-42.8%)
Dec 2000
$1.32 M(-74.1%)
$1.32 M(-40.1%)
Sept 2000
-
$2.20 M(-12.0%)
June 2000
-
$2.50 M(-36.3%)
Mar 2000
-
$3.92 M(-22.8%)
Dec 1999
$5.08 M(+111.8%)
$5.08 M(-21.8%)
Sept 1999
-
$6.50 M(-19.8%)
June 1999
-
$8.10 M(-9.0%)
Mar 1999
-
$8.90 M(+169.7%)
Dec 1998
$2.40 M(-40.0%)
-
Sept 1998
-
$3.30 M(-17.5%)
June 1998
-
$4.00 M(-16.7%)
June 1998
$4.00 M(-38.5%)
-
Mar 1998
-
$4.80 M(-15.8%)
Dec 1997
-
$5.70 M(-6.6%)
Sept 1997
-
$6.10 M(-6.2%)
June 1997
$6.50 M(+132.1%)
$6.50 M(-14.5%)
Mar 1997
-
$7.60 M(+280.0%)
Dec 1996
-
$2.00 M(-16.7%)
Sept 1996
-
$2.40 M(-14.3%)
June 1996
$2.80 M(-12.5%)
$2.80 M(-3.4%)
Sept 1995
-
$2.90 M(-9.4%)
June 1995
$3.20 M(-44.8%)
$3.20 M(-20.0%)
Mar 1995
-
$4.00 M(-13.0%)
Dec 1994
-
$4.60 M(-14.8%)
Sept 1994
-
$5.40 M(-6.9%)
June 1994
$5.80 M(+70.6%)
$5.80 M(-7.9%)
Mar 1994
-
$6.30 M(+133.3%)
Dec 1993
-
$2.70 M(-20.6%)
Sept 1993
-
$3.40 M(0.0%)
June 1993
$3.40 M(-26.1%)
$3.40 M(-10.5%)
Mar 1993
-
$3.80 M(-5.0%)
Dec 1992
-
$4.00 M(-9.1%)
Sept 1992
-
$4.40 M(-4.3%)
June 1992
$4.60 M
$4.60 M(-6.1%)
Mar 1992
-
$4.90 M

FAQ

  • What is Lineage Cell Therapeutics annual stockholders equity?
  • What is the all time high annual shareholders equity for Lineage Cell Therapeutics?
  • What is Lineage Cell Therapeutics annual shareholders equity year-on-year change?
  • What is Lineage Cell Therapeutics quarterly stockholders equity?
  • What is the all time high quarterly shareholders equity for Lineage Cell Therapeutics?
  • What is Lineage Cell Therapeutics quarterly shareholders equity year-on-year change?

What is Lineage Cell Therapeutics annual stockholders equity?

The current annual shareholders equity of LCTX is $63.42 M

What is the all time high annual shareholders equity for Lineage Cell Therapeutics?

Lineage Cell Therapeutics all-time high annual stockholders equity is $162.64 M

What is Lineage Cell Therapeutics annual shareholders equity year-on-year change?

Over the past year, LCTX annual stockholders equity has changed by -$9.92 M (-13.53%)

What is Lineage Cell Therapeutics quarterly stockholders equity?

The current quarterly shareholders equity of LCTX is $66.19 M

What is the all time high quarterly shareholders equity for Lineage Cell Therapeutics?

Lineage Cell Therapeutics all-time high quarterly stockholders equity is $198.29 M

What is Lineage Cell Therapeutics quarterly shareholders equity year-on-year change?

Over the past year, LCTX quarterly stockholders equity has changed by -$1.93 M (-2.83%)